Phaseline

Companies › Jiangsu Simcere Pharmaceutical

Jiangsu Simcere Pharmaceutical: clinical trials, targets and expected readouts

17 active drug programs in 21 registered trials: 15 Phase 1, 6 Phase 3; Oncology, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trilaciclib
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 3MyelosuppressionJul 2027
Suvemcitug–Phase 3Refractory Metastatic Colorectal CancerJan 2028
Everolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Locally Advanced or Metastatic Breast CancerAug 2028
[14C] SIM0270
Selective estrogen receptor degrader (SERD)
ESR1Phase 3Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Healthy Participants; Healthy Adult ParticipantsAug 2028
ENDOSTAR
Recombinant human endostatin; antiangiogenic agent and vascular endothelial growth factor
VEGFAPhase 3Malignant Pleural Effusion–
SIM0237–Phase 1Non-Muscle-Invasive Bladder Cancer (NMIBC)Jan 2027
SIM0388
Docetaxel polymeric micelle formulation (microtubule stabilizer)
TubulinPhase 1Malignant AscitesJun 2027
SIM0508–Phase 1Advanced Solid TumorsJun 2027
SIM0500–Phase 1Relapsed or Refractory Multiple MyelomaSep 2027
SCR-6920 capsule
PRMT5 inhibitor
PRMT5Phase 1Solid TumorOct 2027
SIM0610–Phase 1Advanced Solid TumoursDec 2027
SIM0686–Phase 1Locally Advanced Solid TumorsDec 2027
SIM0613–Phase 1Advanced Solid CancerJun 2028
SIM0532–Phase 1Histologically or Cytologically Confirmed Advanced Solid TumorsJun 2028
SIM0609–Phase 1Advanced Solid CancerDec 2028
SIM0689 for Injection
PD-1/VEGF bispecific antibody
PDCD1, VEGFAPhase 1Neoplasms, MalignantDec 2028
SIM0811–Phase 1Health, Subjective–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05293964[14C] SIM0270Phase 1Breast CancerOncologyDec 2024
NCT04914598ENDOSTARPhase 3Malignant Pleural EffusionOncologyFeb 2025
NCT04914598ENDOSTARPhase 3Malignant Pleural EffusionOncologyFeb 2025
NCT06654791[14C] SIM0270Phase 1Healthy ParticipantsOtherMar 2025
NCT07345364SIM0811Phase 1Health, SubjectiveOtherJun 2026
NCT07357610[14C] SIM0270Phase 1Healthy Adult ParticipantsOtherOct 2026
NCT06186414SIM0237Phase 1Non-Muscle-Invasive Bladder Cancer (NMIBC)OncologyJan 2027
NCT07007988SIM0388Phase 1Malignant AscitesOncologyJun 2027
NCT06686745SIM0508Phase 1Advanced Solid TumorsOncologyJun 2027
NCT07881705TrilaciclibPhase 3MyelosuppressionOncologyJul 2027
NCT06375044SIM0500Phase 1Relapsed or Refractory Multiple MyelomaOncologySep 2027
NCT05528055SCR-6920 capsulePhase 1Solid TumorOncologyOct 2027
NCT07050459SIM0686Phase 1Locally Advanced Solid TumorsOncologyDec 2027
NCT07348211SIM0610Phase 1Advanced Solid TumoursOncologyDec 2027
NCT07361003SuvemcitugPhase 3Refractory Metastatic Colorectal CancerOncologyJan 2028
NCT07618260SIM0613Phase 1Advanced Solid CancerOncologyJun 2028
NCT07749703SIM0532Phase 1Histologically or Cytologically Confirmed Advanced Solid TumorsOncologyJun 2028
NCT06680921EverolimusPhase 3Locally Advanced or Metastatic Breast CancerOncologyAug 2028
NCT06680921[14C] SIM0270Phase 3Locally Advanced or Metastatic Breast CancerOncologyAug 2028
NCT07265921SIM0609Phase 1Advanced Solid CancerOncologyDec 2028
NCT07660432SIM0689 for InjectionPhase 1Neoplasms, MalignantOncologyDec 2028

Targets

VEGFA (2) PDCD1 (1) CDK4 (1) CDK6 (1) Tubulin (1) PRMT5 (1) FKBP1A (1) ESR1 (1)

Companies with the same targets

Roche Pfizer AstraZeneca Akeso Shanghai Henlius Biotech Innovent Biologics (Suzhou) Jiangsu HengRui Medicine AbbVie Eli Lilly Amgen

Companies built like this

Shanghai Hengrui Pharmaceutical Shandong Suncadia Medicine Sichuan Kelun-Biotech Biopharmaceutical Mabwell (Shanghai) Bioscience Akeso

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.